23rd week of 2017 patent applcation highlights part 25 |
Patent application number | Title | Published |
20170158665 | METHOD FOR PREPARING THE ANHYDROUS CRYSTALLINE FORM OF ISONIAZID-DERIVED HYDRAZONE, THUS PRODUCED CRISTALLINE POLYMORPH OF THE ANHYDROUS FORM, USE THEREOF FOR THE TREATMENT OF ALZHEIMER'S DISEASE, PARKINSONISM AND OTHER NEURODEGENERATIVE DISORDERS, AND PHARMACEUTICAL COMPOSITION - The present invention relates to the method for preparing the anhydrous crystalline form of isoniazid-derived hydrazone (8-hydroxyquinoline-2-carboxaldehyde isonicotinoyl hydrazone), to the thus produced polymorph and to the use thereof for the treatment of Alzheimer's disease and parkinsonism, inter alia, and to a pharmaceutical composition. | 2017-06-08 |
20170158666 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 2017-06-08 |
20170158667 | 2-(2,4-DIFLUOROPHENYL)-1,1-DIFLUORO-1-(5-SUBSTITUTED-PYRIDIN-2-YL)-3-(1H-T- ETRAZOL-1-YL)PROPAN-2-OLS AND PROCESSES FOR THEIR PREPARATION - Provided herein are 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1H-tetrazol-1-yl)propan-2-ols and 1-(2,4-difluorophenyl)-2,2-difluoro-2-(5-substituted-pyridin-2-yl)ethanones and processes for their preparation. | 2017-06-08 |
20170158668 | 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME - Provided is a compound represented by general formula (1) or a salt thereof as well as a medicine containing the compound or the salt. | 2017-06-08 |
20170158669 | INDAZOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF - Provided herein are compounds of the formulas (I) and (II): | 2017-06-08 |
20170158670 | PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS - The present disclosure describes pyridineamine compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases. | 2017-06-08 |
20170158671 | PYRIMIDINE COMPOSITIONS, ULTRA PURE COMPOSITIONS AND SALTS THEREOF, METHODS OF MAKING THE SAME, AND METHODS OF USING THE SAME FOR TREATING HISTAMINE H4 RECEPTOR (H4) MEDIATED DISEASES AND CONDITIONS - The present application relates to ultra-pure compositions containing N | 2017-06-08 |
20170158672 | Benzocyanine Compounds - Compounds useful as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided. | 2017-06-08 |
20170158673 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS - The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) | 2017-06-08 |
20170158674 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO - This document discloses molecules having the following formula (“Formula One”): | 2017-06-08 |
20170158675 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO - This document discloses molecules having the following formula (“Formula One”): | 2017-06-08 |
20170158676 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS - The present invention relates to a process of providing the 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid in substantially free form (Compound 1). | 2017-06-08 |
20170158677 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS - Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer. | 2017-06-08 |
20170158678 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS - The present invention is directed to substituted pyridine derivatives, pharmaceutical compositions containing said derivatives and the use of said derivatives in the treatment of disorders mediated by c-fms kinase. The present invention is further directed to a process for the preparation of said substituted pyridine derivatives. | 2017-06-08 |
20170158679 | PROCESS FOR PREPARING A NOVEL CRYSTALLINE FORM OF THIFENSULFURON-METHYL AND USE OF THE SAME - A the crystalline form of thifensulfuron-methyl of formula (I), the crystal preparation process, the analyses of the crystal through various analytical methods and using the crystal to prepare stable agrochemical formulation. The invention also describes the use of various solvents towards the crystalline form preparation conditions. | 2017-06-08 |
20170158680 | HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF - The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease. | 2017-06-08 |
20170158681 | HISTONE DEMETHYLASE INHIBITORS - The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like. | 2017-06-08 |
20170158682 | METHOD FOR PRODUCING FUSED HETEROCYCLIC COMPOUND - A compound represented by formula (4) is produced by a step A of reacting a compound represented by formula (2): | 2017-06-08 |
20170158683 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds. | 2017-06-08 |
20170158684 | NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT - The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media. | 2017-06-08 |
20170158685 | HISTONE DEMETHYLASE INHIBITORS - The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like. | 2017-06-08 |
20170158686 | Compounds Useful as Raf Kinase Inhibitors - The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases. | 2017-06-08 |
20170158687 | ATX MODULATING AGENTS - Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer. | 2017-06-08 |
20170158688 | Imidazopyridine Derivatives as Modulators of TNF Activity - A series of substituted 1H imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. | 2017-06-08 |
20170158689 | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS - The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer. | 2017-06-08 |
20170158690 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR - Disclosed are compounds of Formula I: | 2017-06-08 |
20170158691 | Derivatives And Methods Of Treating Hepatitis B Infections - Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject. | 2017-06-08 |
20170158692 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN - Provided are compounds, compositions and methods for inhibiting fascin activity or treating a condition or disorder mediated by fascin activity in a subject in need thereof. | 2017-06-08 |
20170158693 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL - The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT | 2017-06-08 |
20170158694 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY - Compounds of formula (I), defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases. | 2017-06-08 |
20170158695 | Method For Preparation of Alkylated or Fluoro, Chloro and Fluorochloro Alkylated Compounds By Heterogeneous Catalysis - The invention discloses a method for preparation of alkylated or fluoro, chloro and fluorochloro alkylated compounds by a heterogeneous Pt/C-catalyzed alkylation or fluoro, chloro and fluorochloro alkylation with alkyl halides or with fluoro, chloro and fluorochloro alkyl halides in the presence of Cs | 2017-06-08 |
20170158696 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS - The present invention provides N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases. | 2017-06-08 |
20170158697 | Protein Kinase Inhibitors - The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to processes for the preparation of these compounds, to the pharmaceutical composition comprising them, and to their use in the treatment of proliferative, inflammatory, infectious or autoimmune diseases, disorder or condition in which protein kinase activity is implicated. | 2017-06-08 |
20170158698 | TrKA Kinase Inhibitors, Compositions and Methods Thereof - The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. | 2017-06-08 |
20170158699 | ADDITION SALTS OF (S)-2-(1-(6-AMINO-5-CYANOPYRIMIDIN-4-YLAMINO)ETHYL)-4-OXO-3-PHENYL-3,4-DI- HYDROPYRROLO[1,2-F][1,2,4]TRIAZINE-5-CARBONITRILE - The present invention is directed to novel pharmaceutically acceptable, addition salts of (S)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile with sulfonic acid derivatives, in particular with methanesulfonic acid, naphthalene-2-sulfonic acid and para-toluenesulfonic acid, and pharmaceutically acceptable solvates thereof, and their use as Phosphoinositide 3-Kinase (PI3K) inhibitors. | 2017-06-08 |
20170158700 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES - The present invention provides compounds of formula (I) (Formula (I)) and pharmaceutically acceptable salts thereof, wherein Q, X % X | 2017-06-08 |
20170158701 | PROCESS FOR PREPARING CHIRAL DIPEPTIDYL PEPTIDASE-IV INHIBITORS - A process for preparing a compound of structural Formula Ia: comprising Boc deprotection with TFA of, reductive amination of: | 2017-06-08 |
20170158702 | MULTIVALENT RAS BINDING COMPOUNDS - Described herein are compounds that modulate Ras signaling, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with altered Ras signaling. Further described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds and methods of using such compounds in the treatment of cell proliferative disorders, including cancer. | 2017-06-08 |
20170158703 | METHOD FOR PRODUCING SPIROOXINDOLE DERIVATIVE - The present invention is intended to provide a method for efficiently producing and providing a compound having a spirooxindole skeleton, for example, a compound having a spirooxindole skeleton and having antitumor activity that inhibits the interaction between Mdm2 protein and p53 protein, or an intermediate thereof, using an asymmetric catalyst. A compound having an optically active tricyclic dispiroindole skeleton is efficiently obtained through a catalytic asymmetric 1,3-dipolar cycloaddition reaction using ketimine as a reaction substrate and using a chiral ligand and a Lewis acid. | 2017-06-08 |
20170158704 | PYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN-INHIBITORY ACTIVITY - A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt: | 2017-06-08 |
20170158705 | METHOD FOR PREPARING ERIBULIN INTERMEDIATE - Intermediates used in the synthesis of Eribulin and methods for preparing the intermediates are described. For example, a compound of formula IV and a method for preparing the compound are described, wherein R | 2017-06-08 |
20170158706 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C - The present application provides a compound of formula (I) | 2017-06-08 |
20170158707 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME - The present invention is generally directed towards compounds capable of binding the aryl hydrocarbon receptor and modulating its activity, methods of treating inflammatory conditions such as Crohn's disease using such compounds, and pharmaceutical compositions comprising such compounds. Also provided are methods of increasing levels of IL-22 in a subject and/or decreasing levels of IFN-γ in a subject. | 2017-06-08 |
20170158708 | ANTIBACTERIAL COMPOUNDS - The invention relates to antibacterial and anti-mycobacterial drug compounds of formula I. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also relates to uses of the derivatives in treating bacterial infections, and methods of treating bacterial infections. The invention is also directed to antibacterial drug compounds capable of treating bacterial infections that are currently hard to treat with existing drug compounds, e.g., those caused by resistant bacterial or mycobacterial strains. | 2017-06-08 |
20170158709 | BROMODOMAIN INHIBITORS - The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease. | 2017-06-08 |
20170158710 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS - The present disclosure relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer. | 2017-06-08 |
20170158711 | NOVEL INDUSTRIAL CRYSTALLIZATION METHOD OF CEFUROXIME SODIUM AND PREPARATION THEREOF - It discloses a new industrial crystallization method of Cefuroxime Sodium, wherein supercritical fluid extraction technology and traditional crystalline technology are combined to realize the recrystallization of Cefuroxime Sodium. Processes such as extraction, adsorption, crystallization and drying are carried out with a supercritical fluid, a solvent, an extraction cell and a crystallization tank to realize the recrystallization of Cefuroxime Sodium under a specific pressure at a specific temperature. | 2017-06-08 |
20170158712 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (Ia): | 2017-06-08 |
20170158713 | METHOD OF TREATING CANCER AND GOLD(III) COMPLEXES AS ANTI-CANCER AGENTS - A method for treating cancer and gold(III) complexes with diaminocyclohexane ligand as anticancer agents. Also described are a pharmaceutical composition incorporating the gold(III) complexes and a method of synthesizing the gold(III) complexes. | 2017-06-08 |
20170158714 | Preparation and Medical Use of Triazenes - The present invention relates to a novel method for preparing triazenes. Further, the invention relates to novel triazenes and the use of N | 2017-06-08 |
20170158715 | LIQUID CRYSTAL VERTICAL ALIGNMENT AGENT, LIQUID CRYSTAL DISPLAY ELEMENT AND MANUFACTURE METHOD OF LIQUID CRYSTAL DISPLAY ELEMENT - The present invention provides a liquid crystal vertical alignment agent, and the liquid crystal vertical alignment agent can make the liquid crystal molecules vertically orientated relative to the substrate surface. The liquid crystal vertical alignment agent makes a cheap price, a stable performance and can make the liquid crystal molecules be vertically aligned. The alignment film such as polyimide (PI) in the present liquid crystal display (such as TFT-LCD) can be replaced, which is beneficial for raising the display performance of the liquid crystal display. The present invention further provides a liquid crystal display element, and the liquid crystal display element utilizes the said liquid crystal vertical alignment agent to make the alignment of the liquid crystal molecules in the vertical direction more consistent and have long term stability. | 2017-06-08 |
20170158716 | METHOD FOR PRODUCING SILANE COMPOUND HAVING SULFONYL BOND - A method of producing a silane compound having a Formula (1) sulfonyl bond includes reacting a Formula (I) chlorosulfonyl compound with sodium sulfite in water as a solvent in the presence of a base, to produce a Formula (II) sulfinic acid sodium salt: and adding an aromatic hydrocarbon solvent to carry out azeotropic dehydration, and adding an aprotic polar solvent and a Formula (III) chloroalkylsilane compound. | 2017-06-08 |
20170158717 | AMINOSILICONE SOLVENT RECOVERY METHODS AND SYSTEMS - The present invention is directed to aminosilicone solvent recovery methods and systems. The methods and systems disclosed herein may be used to recover aminosilicone solvent from a carbon dioxide containing vapor stream, for example, a vapor stream that leaves an aminosilicone solvent desorber apparatus. The methods and systems of the invention utilize a first condensation process at a temperature from about 80° C. to about 150° C. and a second condensation process at a temperature from about 5° C. to about 75° C. The first condensation process yields recovered aminosilicone solvent. The second condensation process yields water. | 2017-06-08 |
20170158718 | TITANIUM (IV) COMPOUNDS AND METHODS OF FORMING HETEROCYCLIC COMPOUNDS USING SAME - The present disclosure provides Titanium (IV) compounds and methods of making heterocyclic compounds such as pyrroles using Titanium (IV) compounds. In certain embodiments, the Titanium (IV) compound is present in catalytic amounts. | 2017-06-08 |
20170158719 | PROCESS FOR REDUCING THE CHLORINE CONTENT OF ORGANOTETRAPHOSPHITES - Universally usable process for reducing the chlorine content of organotetraphosphites. | 2017-06-08 |
20170158720 | Antimicrobial Compounds - An antimicrobial compound, as well as the salts, derivatives and analogues thereof, said compound being represented by the general formula (I): | 2017-06-08 |
20170158721 | HETEROCYCLIC SELENAPHOSPHITES AND PROCESS FOR PREPARATION THEREOF - Novel heterocyclic selenaphosphites, process for preparation thereof and use thereof as ligand for employment in complexes. | 2017-06-08 |
20170158722 | HETEROCYCLIC SELENOPHOSPHITES AND METHOD FOR THE PREPARATION THEREOF - Novel heterocyclic selenophosphites, method for preparation thereof and use thereof as ligand unit for preparing ligands for use in complexes. | 2017-06-08 |
20170158723 | HETEROCYCLIC SELENAMONOPHOSPHITES PROTECTED ON A HYDROXYL GROUP AND PROCESSES FOR PREPARATION THEREOF - Novel heterocyclic selenamonophosphites protected on the hydroxyl group, processes for preparation thereof and the use thereof as ligand. | 2017-06-08 |
20170158724 | Novel Compounds - A compound of Formula (I) | 2017-06-08 |
20170158725 | PRODRUG COMPOUNDS AND USES THEROF - Provided herein are cyclic phosphorus-containing prodrug compounds, their preparation and their uses, such as treating diseases via modulating molecular targets in the liver. | 2017-06-08 |
20170158726 | ORGANODIARYL SELENOXIDES AND PROCESS FOR PREPARATION THEREOF - Novel organodiaryl selenoxides and processes for preparation thereof, and use thereof as ligand in complexes. | 2017-06-08 |
20170158727 | HAMAMELITANNIN ANALOGUES AND USES THEREOF - The present invention relates to hamamelitannin analogues, pharmaceutical compositions comprising the same, and combinations thereof with anti-microbial agents such as antibiotics or disinfectants. It in particular relates to the use of the compounds, compositions and combinations according to this invention in human or veterinary medicine, more in particular for use in the prevention and/or treatment of bacterial infections, such as | 2017-06-08 |
20170158728 | SULFATED-GLYCOLIPIDS AS ADJUVANTS FOR VACCINES - A synthetic charged glycolipid is described comprising a sulfated saccharide group covalently linked to the tree sn-1 hydroxyl group of the glycerol backbone of an archaeal core lipid via a beta linkage. The synthetic charged glycolipids include compounds of formula I wherein n is 0 or 1; R is hydrogen or hydroxyl; and Y is hydrogen or a sulfate group, at least one Y being a sulfate group; and including pharmaceutically acceptable salts thereof. The sulfated glycolipid produces stable archaeosomes at a mol % ratio of from 100:0 to 30:70 (sulfated glycolipid: uncharged glycolipid) and which induce a protective immune response, including CD8 | 2017-06-08 |
20170158729 | METHOD OF SYNTHESIZING 25-HYDROXY CHOLESTEROL - The present invention discloses a method for synthesizing 25-hydroxy cholesterol. The method is as below: subjecting 24-dehydrocholesterol derivative as a raw material, which undergoes an addition reaction with a hydroxyl containing reagent in an organic solvent under catalysis, and then hydrolyzing the reaction product and separating to obtain 25-hydroxy cholesterol. The present invention adopts hydroxyl containing reagents such as water, formic acid, acetic acid, propionic acid, butyric acid, benzoic acid, p-methyl benzoic acid to replace the commonly used extremely toxic reagents such as Cr reagent, Hg reagent and polyfluorinated acetone in the prior art. The raw materials of the present invention are easily available, and have low effect on environment. The operation and post treatment are convenient. Moreover, the method has the advantages of mild reaction conditions, simple operation, good selectivity, high efficiency, high yield, simple post treatment, easy product separation, less three wastes and easy industrialization. | 2017-06-08 |
20170158730 | HYDROXYSTEROID COMPOUNDS, THEIR INTERMEDIATES, PROCESS OF PREPARATION, COMPOSITION AND USES THEREOF - The present invention relates to novel steroidal compounds of formula (I), process for preparation of the same and composition comprising these compounds. | 2017-06-08 |
20170158731 | NUCLEOPHILE-REACTIVE SULFONATED COMPOUNDS FOR THE (RADIO)LABELLING OF (BIO)MOLECULES; PRECURSORS AND CONJUGATES THEREOF - Nucleophile-reactive sulfonated compounds used as precursors to (radio)labelled (bio)molecules are produced by pre-introduction of a nucleophilic compound R* through an unusual nucleophile-induced ring-opening reaction of the sultone moiety of the precursor. The precursors and compounds conform to respective formulae (Ip) and (I): | 2017-06-08 |
20170158732 | VIRUS REDUCTION METHOD - Methods are provided for enhancing reduction of virus and viral DNA levels in protein preparations. | 2017-06-08 |
20170158733 | PROCESS FOR THE PREPARATION OF RAMIPRIL - An enantioselective process for the production of (2S,3aS,6aS)-cyclopenta[b]pyrrole-2-carboxylic acid and its conversion into Ramipril is provided. | 2017-06-08 |
20170158734 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION - The present disclosure relates to novel compounds and pharmaceutical compositions thereof which are useful as inhibitors of proteasomes. The compounds provided herein have improved proteasome potency and selectivity, and increased aqueous solubility, and are useful in treating various conditions or diseases associated with proteasomes. | 2017-06-08 |
20170158735 | METHOD FOR PRODUCING A RECOMBINANT PEPTIDE AND RESULTANT PEPTIDE - The invention relates to peptides with the following general formula: | 2017-06-08 |
20170158736 | COMPOSITIONS AND METHODS FOR TREATING MRSA INFECTIONS AND FOR SENSITIZING MRSA TO BETA-LACTAM ANTIBIOTICS - Provided herein are compounds and compositions having antibiotic activity against methicillin resistant | 2017-06-08 |
20170158737 | CANCER STEM CELL TARGETING PEPTIDE AND USE THEREOF - A synthetic peptide that targets cancer stem cells is provided. The peptide consists of the amino acid sequence of anyone of SEQ ID NO: 1 to SEQ ID NO: 15. Also provided is a composition comprising said synthetic peptide with a therapeutic agent fused thereto, and a pharmaceutically acceptable carrier or diluent. Further provided is a method of screening a peptide specifically targeting to a cancer stem cell. The method comprises the steps of establishing an oligopeptide library by using a phage expression system, contacting the library with a culture of bulk tumor cells of a cancer cell line, contacting the phages which do not bind to the bulk tumor cells with a culture of cancer stem cells of said cancer cell line, and screening a peptide specifically targeting to a cancer stem cell from the phages which bind to the cancer stem cells. | 2017-06-08 |
20170158738 | MULTIPLEXED SAME TYPE-ANTIGENIC PEPTIDE - The present invention provides a synthetic peptide capable of inducing an antibody to an autoantigen, and specifically, provides: a multiplexed same type-antigenic peptide having a dendritic core and B-cell recognition peptides, wherein the multiplexed same type-antigenic peptide comprises 4 to 8 B-cell recognition peptides of the same type that are bound to the terminal ends of the dendritic core directly or via a spacer, and each B-cell recognition peptide is bound to the terminal end of the dendritic core directly or via a spacer; an antibody production-inducing agent having the peptides; and a method for producing the peptide. | 2017-06-08 |
20170158739 | MINICIRCLE DNA VECTOR VACCINE PLATFORM FOR FOOT-AND-MOUTH DISEASE AND METHODS THEREOF - This application is directed generally to minicircle DNA vectors for the vaccination of foot-and-mouth disease (FMD). The transgene expression cassette in the minicircle DNA vector includes: a eukaryotic translation initiation nucleotide sequence, a mutant nucleotide sequence that encodes a foot-and-mouth disease virus (FMDV) capsid polyprotein precursor that contains at least one mutation to eliminate a restriction enzyme recognition site, a nucleotide sequence that encodes a protease that cleaves the FMDV capsid polyprotein precursor into a plurality of FMDV capsid proteins and a translational regulatory element to regulate the expression of the protease. The minicircle DNA vectors can be transfected directly into the cell of a mammalian host. When transfected into the mammalian host cell, virus-like particles can be produced intrinsically to stimulate the mammalian host's immune system to develop adaptive immunity toward foot-and-mouth disease. | 2017-06-08 |
20170158740 | A DENGUE VIRUS CHIMERIC POLYEPITOPE COMPOSED OF FRAGMENTS OF NON-STRUCTURAL PROTEINS AND ITS USE IN AN IMMUNOGENIC COMPOSITION AGAINST DENGUE VIRUS INFECTION - The present invention is directed to a dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection. The present invention provides means, in particular polynucleotides, vectors, cells and methods to produce vectors expressing said chimeric polyepitopes, in particular vectors consisting of recombinant measles virus (MV) particles. The present invention also relates to the use of the recombinant MV particles, in particular under the form of a composition or of a vaccine, for the prevention and/or treatment of a dengue virus infection. | 2017-06-08 |
20170158741 | PEPTIDES INCLUDING A BINDING DOMAIN OF THE VIRAL PHOSPHOPROTEIN (P) SUBUNIT TO THE VIRAL RNA FREE NUCLEOPROTEIN (N0) - The invention related to isolated peptides including a binding domain of the viral phosphoprotein (P) subunit to the viral RNA free nucleoprotein (N | 2017-06-08 |
20170158742 | BIOTINYLATED PROTEIN - Disclosed are methods of screening a library of molecules to identify or select one or more molecules which selectively bind to a fused protein, or fragment thereof. The fused protein comprises a moiety and a protein selected from a group consisting of | 2017-06-08 |
20170158743 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE - The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients. | 2017-06-08 |
20170158744 | MIMOTOPES OF ALPHA-SYNUCLEIN AND VACCINES THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS - A method of treating a synucleinopathy with a peptide (C)DQPVLPD (SEQ ID NO: 59), (C)DMPVLPD (SEQ ID NO: 60), (C)DSPVLPD (SEQ ID NO: 61), (C)DQPVLPDN (SEQ ID NO: 64), (C)DMPVLPDN (SEQ ID NO: 65), (C)DSPVLPDN (SEQ ID NO: 66), (C)HDRPVTPD (SEQ ID NO: 70), (C)DRPVTPD (SEQ ID NO: 71), (C)DVPVLPD (SEQ ID NO: 72), (C)DTPVYPD (SEQ ID NO: 73), (C)DTPVIPD (SEQ ID NO: 74), (C)HDRPVTPDN (SEQ ID NO: 75), (C)DRPVTPDN (SEQ ID NO: 76), (C)DVPVLPDN (SEQ ID NO: 78), (C)DTPVYPDN (SEQ ID NO: 79), (C)DQPVLPDG (SEQ ID NO: 81), (C)DMPVLPDG (SEQ ID NO: 82), (C)DSPVLPDG (SEQ ID NO: 83), (C)DHPVHPDS (SEQ ID NO: 86), (C)DMPVSPDR (SEQ ID NO: 87), (C)DRPVYPDI (SEQ ID NO: 90), (C)DHPVTPDR (SEQ ID NO: 91), (C)DTPVLPDS (SEQ ID NO: 93), (C)DMPVTPDT (SEQ ID NO: 94), (C)DAPVTPDT (SEQ ID NO: 95), (C)DSPVVPDN (SEQ ID NO: 96), (C)DLPVTPDR (SEQ ID NO: 97), (C)DSPVHPDT (SEQ ID NO: 98), (C)DAPVRPDS (SEQ ID NO: 99), (C)DMPVLPDG (SEQ ID NO: 100), (C)DRPVQPDR (SEQ ID NO: 102), (C)YDRPVQPDR (SEQ ID NO: 103), (C)DMPVDADN (SEQ ID NO: 105), DQPVLPD(C) (SEQ ID NO: 106), and DMPVLPD(C) (SEQ ID NO: 107. | 2017-06-08 |
20170158745 | IDR PEPTIDE COMPOSITIONS AND USE THEREOF FOR TREATMENT OF TH2-DYSREGULATED INFLAMMATORY CONDITIONS - A composition for treating or preventing a Th2-dysregulated inflammatory condition wherein the composition comprises a therapeutically effective amount of one or more IDR peptides. Use of IDR peptides or a composition comprising IDR peptides for treating or preventing a Th2-dysregulated inflammatory condition. The Th2-dysregulated inflammatory condition includes allergy or atopy, for example allergic asthma. | 2017-06-08 |
20170158746 | MODIFIED INTERLEUKIN-7 PROTEIN AND USES THEREOF - The present invention provides a modified interleukin-7 and a use thereof. The modified IL-7 or an IL-7 fusion protein of the present invention comprising the same can be obtained in high yield, and biologically active in viral infection and cancer models. Therefore, they can be used for the prevention and treatment of various diseases. | 2017-06-08 |
20170158747 | ANTIBODY CYTOKINE ENGRAFTED COMPOSITIONS AND METHODS OF USE FOR IMMUNOREGULATION - The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder. | 2017-06-08 |
20170158748 | GLUCOSE-REGULATING POLYPEPTIDES AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising glucose regulating peptides linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of glucose regulating peptide-related diseases, disorders, and conditions. | 2017-06-08 |
20170158749 | CHIMERIC ANTIGEN RECEPTORS (CAR) AND METHODS FOR MAKING AND USING THE SAME - Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically targeting cells that express elevated levels of antigen (e.g., cancer cells) with CAR T-cell therapies are provided. | 2017-06-08 |
20170158750 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2017-06-08 |
20170158751 | MODULATING DISEASE THROUGH GENETIC ENGINEERING OF PLANTS - In certain embodiments transgenic plants (e.g., transgenic tomatoes) are provided that comprise cells that express a peptide one or more domains of which comprise the amino acid sequence of an apolipoprotein or apolipoprotein mimetic peptide where the peptide has biological activity (e.g., lowers SAA, and/or increases paroxonase activity, and/or improves HDL inflammatory index, etc.) when the plant and/or the peptide is fed to a mammal. | 2017-06-08 |
20170158752 | MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF - The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof. | 2017-06-08 |
20170158753 | MONOCLONAL ANTIBODIES DIRECTED AGAINST ENVELOPE GLYCOPROTEINS FROM MULTIPLE FILOVIRUS SPECIES - The disclosure provides binding molecules, e.g., antibodies or antigen-binding fragments thereof, that can bind to orthologous epitopes found on two or more filovirus species or strains. | 2017-06-08 |
20170158754 | HUMAN MONOCLONAL ANTIBODIES DERIVED FROM HUMAN B CELLS AND HAVING NEUTRALIZING ACTIVITY AGAINST INFLUENZA A VIRUSES - The present invention relates to human monoclonal antibodies derived from human B cells present in the blood of patients who had recovered from infection with influenza A viruses, wherein the monoclonal antibodies have neutralizing activity against influenza A viruses. The anti-influenza A virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza A virus selected from the group consisting of influenza A virus H1, H2 and H5 subtypes, and thus it is useful for the prevention and treatment of a disease caused by the influenza A virus and is also useful for diagnosis of influenza A virus infection. | 2017-06-08 |
20170158755 | ANTI-LAMININ4 ANTIBODIES SPECIFIC FOR LG1-3 - The invention provides antibodies that specifically bind to the LG1-3 modules of the G domain of laminin α4. The antibodies have the capacity to inhibit binding of laminin α4 to MCAM. The antibodies can be used for inhibiting undesired immune responses, treatment of cancer, or treatment of obesity or obesity-related diseases, among other applications. | 2017-06-08 |
20170158756 | CANINIZED ANTI-NGF ANTIBODIES AND METHODS THEREOF - The invention provides novel caninized anti-NGF antibodies (such as caninized anti-NGF antagonist antibodies and antigen binding proteins), and polynucleotides encoding the same. The invention further provides use of said antibodies or antigen binding proteins and/or nucleotides in the treatment and/or prevention of NGF related disorders, particularly pain. | 2017-06-08 |
20170158757 | IP-10 ANTIBODIES AND THEIR USES - The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases. | 2017-06-08 |
20170158758 | LOW ACIDIC SPECIES COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME - The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNFα is detrimental, are also provided. | 2017-06-08 |
20170158759 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS - A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | 2017-06-08 |
20170158760 | Isolation and Purification of Antibodies Using Protein A Affinity Chromatography - Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography, preferably Protein A affinity, ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention. | 2017-06-08 |
20170158761 | BINDING INHIBITOR BETWEEN TCTP DIMER TYPE IGE-DEPENDENT HISTAMINE RELEASING FACTOR AND RECEPTOR THEREOF, AND USE THEREOF - The present invention relates to a receptor-binding domain of an IgE-dependent histamine releasing factor (HRF), and a use thereof, and more specifically, ascertains, as an HRF structual region, and a FL domain and an H2 domain which bind to a receptor of HRF existing in a cell membrane, ascertains the C-terminus domain of the HRF, and ascertains that a material binding thereto inhibits IL-8 secretion, thereby determining that the FL and H2 domains and the C-terminus domain can be utilized in: the development of a therapeutic agent for treatment and prevention of HRF-related disease including allergic diseases such as asthma, bronchitis, chronic obstructive pulmonary disease, bronchiectasis, rhinitis, atopic dermatitis, hives (urticaria), hay fever, conjunctivitis, and anaphylaxis; inflammatory diseases such as bronchitis, pneumonia, arthritis, nephritis, psoriasis, dermatitis, Crohn's disease, enteritis, gingivitis, arteriosclerosis, coronary arteritis, hepatitis, Behcet's disease, bladder cancer, prostatitis, pyelonephritis, glomerulonephritis, osteomyelitis, thyroiditis, uveitis, abdominal cavity inflammation, meningitis, pulmonary fibrosis and rheumatoid arthritis; and malaria, and a method for screening for the HRF-related diseases. | 2017-06-08 |
20170158762 | ANTIBODIES DIRECTED AGAINST DISCOIDIN DOMAIN RECEPTOR FAMILY, MEMBER 1 (DDR1) - The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to Discoidin Domain Receptor Family, Member 1 (DDR1). The invention provides a DDR1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the DDR1-binding agent to treat a DDR1-mediated disease. | 2017-06-08 |
20170158763 | HUMANIZED ANTIBODIES WITH INCREASED STABILITY - The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders. | 2017-06-08 |
20170158764 | ANTI-CANINE PD-1 ANTIBODY OR ANTI-CANINE PD-L1 ANTIBODY - The object of the present invention is to provide an anti-canine PD-1 antibody or an anti-canine PD-L1 antibody, an agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody, a method for inhibiting binding between a canine PD-1 and a canine PD-L1 comprising using such an antibody, and a gene encoding such an antibody. An anti-canine PD-1 antibody that specifically binds to a canine PD-1 consisting of the amino acid sequence set forth in SEQ ID NO: 1 and an anti-canine PD-L1 antibody that specifically binds to a canine PD-L1 consisting of the amino acid sequence set forth in SEQ ID NO: 6 are produced. An agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody is also produced. | 2017-06-08 |